FLAG-ビオチンタンデム精製による架橋と免疫沈降によるタンパク質RNA相互作用のトランスクリプトーム全体プロファイリング

Executive Industry Relevance

Direct mapping of protein-RNA interactions is critical for target validation and mechanistic de-risking in early discovery pipelines. The Fbio CLIP-seq method enables transcriptome-wide identification of direct RNA-binding protein targets without reliance on isotopes or protein-specific antibodies, reducing confounding from indirect interactions. This capability enhances predictive confidence and supports risk-adjusted portfolio decisions in RNA-targeted drug discovery.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables transcriptome-wide interrogation of direct protein-RNA interactions for functional target validation.
• Reduces mechanistic ambiguity by eliminating indirect RNA-binding protein contaminants.
• Supports predictive confidence in target engagement and pathway mapping.
• Facilitates triage of RNA-binding proteins based on direct interaction profiles.

Screening & Assay Development

• Provides a standardized, antibody-free workflow for preparing validated protein-RNA complexes.
• Delivers quantitative readouts of direct binding events suitable for downstream screening.
• Improves reproducibility and scalability by removing isotope and antibody dependencies.
• Enables reliable evaluation of compound effects on protein-RNA interactions.

Translational & Preclinical Research

• Aligns with disease-relevant systems by profiling endogenous interactions in mammalian cells.
• Supports continuity from discovery to preclinical validation by mapping direct RNA targets.
• De-risks translational biomarker selection through high-specificity interaction data.
• Facilitates risk-adjusted advancement of RNA-targeted therapeutic programs.

Pipeline & Workflow Integration

The Fbio CLIP-seq method integrates at the interface of early discovery and lead identification, providing direct evidence of protein-RNA interactions for target validation and assay development.

• Discovery Biology: Supports hypothesis testing and pathway clarification by mapping direct RNA-binding protein targets.
• Screening: Delivers reproducible, quantitative outputs for compound screening and assay standardization.
• Analytics: Enables transcriptome-wide comparison of binding patterns and motif enrichment.
• Translational Research: Connects discovery findings to preclinical models by profiling interactions in disease-relevant cell types.
• Enterprise Reuse: Provides a reusable, antibody-independent platform for diverse RNA-binding protein studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
• Operational Value: Streamlines workflows through antibody-free, isotope-free, and scalable purification steps.
• Strategic Value: Enables more informed go/no-go decisions and reduces late-stage biological risk.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of RNA-targeted assets.

Implementation Considerations

• Requires expertise in RNA-protein biochemistry and cross-linking techniques.
• Needs access to UV cross-linking, FLAG and streptavidin bead purification, and high-throughput sequencing infrastructure.
• Demands rigorous cross-team standardization for reproducibility and data comparability.
• Adaptable to various mammalian cell models with protocol optimization.
• Potential limitations include requirement for tagged protein expression and careful validation of purification efficiency.

Biopharma FAQs